

THERAPEUTIC PIPELINE

Check out our Pipeline and replenish yours

Therapy Area	TARGET ID	TARGET - HIT	LEAD SERIES	LEAD OPTIMISATION	PRECLINICAL	CLINICAL
Oncology	Anti-ADAM10 (mAb)				HER-2 positive and chemo-resistant cancers; A	
	KAT6A/B inhibitors (small molecule)*			Haematological cancers		
	Dual-targeted BET/PI3K inhibitors (small molecule)			Haematological and other cancers		
Inflammation & immunity	Anti-CXCR3 (mAb)				AI diseases/NASH/IBD	
	Anti-CCR6 (mAb)			AI diseases		
	S1P receptor modulators (small molecule)				IBD	
	RAGE modulators (peptide)			Immunomodulator		
	Anti-inflammatory (small molecule) - 505(b)2				Harlequin ichthyosis (orphan skin indication)	
	Kv1.3 inhibitors (peptide)*				AI diseases	
	Medicinal supplement					AI diseases/Type I diabetes
Infectious Diseases	Anti- α -Plasminogen (mAb)			C.difficile (and others)		
	Antibacterial (small molecule drug combination) - 505(b)2				C.difficile	
	Bedaquiline derivatives (small molecule)			TB		
	Antimicrobial iNOS-SPSB inhibitors (peptide)				Protozoal and bacterial infections	
CVD / Fibrosis / Metabolic Diseases	Selective mineralocorticoid receptor inhibitors (small molecule)			Heart failure and cardiac fibrosis		
	Exosome/relaxin combination (biologic)*				Lung fibrosis	
	GC Rx inhibitors (small molecule and combination)			Obesity		
	Anti-vWF (mAb)				Thrombosis	
	PI3KC2 α blockers (small molecule)			Thrombosis		
CNS	Inhibitors of undisclosed target (miRNA)			Huntington's, Alzheimer's and Parkinson's Diseases		
	RAGE modulators (DNA)			Immunomodulator		
Women's Health	MTX + gefitinib (small molecule drug combination)					Ectopic pregnancy
	Super-GDF9 (biologic)				Female infertility (IVM)	
	Inhibin analogues (biologic)				Post-menopausal complications	
	AMH analogues (biologic)			Oncofertility		

* Under negotiation

Biomedical Opportunities



CELL THERAPY / REGENERATIVE MEDICINE

CAR-T -Two novel targets for boosting CAR-T activation (oncology)

Exosomes from amniotic stem cells (fibrosis and neurodegenerative diseases)



VACCINES

MicroCube vaccine platform - bioengineered protein crystals to present a range of antigens (oncology and infectious diseases)

CLEC9A mAb vaccine delivery platform (oncology and infectious diseases)



DRUG DELIVERY

Functionally tuneable peptide hydrogels for sustained delivery (small molecule, cell therapy, nucleic acids)

Lipopeptide-based nanoparticle gene delivery system

Anti-abuse drug formulation


'Drug on demand' - stimuli-responsive lipid nanostructures



DIAGNOSTICS

PET ligand for MS treatment; PET ligand for oncology

Diagnostic for personalised treatment of CF



ASSAYS

Anti-viral nuclear transport assay (validated screen plus hits)

Brain injury and stroke model (NHP)

Monash Technology Research Platforms

Imaging technologies including Cryo EM, X-ray

Fragment screening

Monash Antibody Technologies Facility

Centre for Drug Candidate Optimisation

Monash Animal Research Platform (CRISPR)

All platforms ISO-accredited: <https://www.monash.edu/research/infrastructure>